frontiers

Supplementary Material

Challenges in drug discovery and description, targeting *Leishmania spp.*: enzymes, structural proteins and transporters

Alexis Mendoza-León,[1*]María Luisa Serrano G.,[2*]Alicia Ponte-Sucre[3*]

[1] Instituto de Biología Experimental (IBE). Facultad de Ciencias. Instituto de Medicina Tropical (IMT), Facultad de Medicina. Universidad Central de Venezuela (UCV). Caracas, Venezuela.

[2] Unidad de Química Medicinal, Facultad de Farmacia. UCV. Caracas, Venezuela.

[3] Laboratorio de Fisiología Molecular. Facultad de Medicina. UCV. Caracas, Venezuela.

***Correspondence authors:**

Alexis Mendoza-León: amendoza50@gmail.com

Maria Luisa Serrano: maria.serrano@ucv.ve

Alicia Ponte Sucre: aiponte@gmail.com

Keywords: Leishmaniasis, target, drug, treatment, tubulin, modelling, glibenclamide

1 Supplementary Table 2: Selected ABC transporter (P-gp-specific) inhibitors[a]

Pharmacological group	*Name of the individual drugs*
Analeptics	Almitrine
Antiarythmics	Amiodarone, lidocaine, quinidineb
Antibiotics	Clarithromycine, erythromicine
Anticancer drugs	Actinomycine D, doxorubicin, vinblastine, biricodar (VX-17) [c], valspodar (PSC-833) **[c]**, elacridar (GF120918) [d], tariquidar (XR9576) **[d]**, zosuquidar (LY335979) [d], laniquidar (R101933) **[d]**, ONT-093 **[d]**.
Antidepressants	Chlorimipramine, imipramine, paroxetine
Antiestrogens	Tamoxifen [b], toremifena [b]
Antihistamines	Terfenadine
Anti-parasitic	Chloroquine, emetine, hydroxicholoroquine, quinacrine, quinine
Calcium channel blockers	Bepridil, diltiazem, felopidine, nifedipine, nisolpidine, nitrendipine, tiapamil, verapamil **[b]**
Coronary vasodilators	Dipyrodamole
Diuretics	Amiloride
HIV protease inhibitors	Indinavir, retanavir, ritonavir, sequinavir
Immunosupressants	Cyclosporin A **[b]**, FK 506, PSC833
Neuroleptics	Reserpine **[b]**, yohimbine **[b]**
Local anesthetics	Bipucaine
Proton pump inhibitors	Esomeprezole, lansoprazole, omeprazole
Steroid hormones	Progesterone
Surfactants	Triton X-100, Tween 80, vremophor-EL
Toxic peptides	N-acetyl-leucyl-leucinal, gramcidine, D, valinomycin
Others	GF120918 **[c]**, LY335979**[d]**, MS-209 **[c]**, OC144093 **[d]**, PSC-833**[c]**, R101933 **[d]**, R-verapamil **[c]**, VX-710 **[c]**, VX-853 **[c]**, XR9576 **[d]**

---

[a] Modified from: Wiese M, Pajeva IK. Structure-activity relationships of multidrug resistance reversers. *Curr Med Chem* (2001) 8(6):685-713. doi: 10.2174/0929867013373138; Lage H. ABC-transporters: implications on drug resistance from microorganisms to human cancers. *Int J Antimicrob Agents* (2003) 22(3):188-99. doi: 10.1016/s0924-8579(03)00203-6.; Varma MV, Ashokraj Y, Dey CS, Panchagnula R. P-glycoprotein inhibitors and their screening: a perspective from bioavailability enhancement. *Pharmacol Res* (2003) 48(4):347-59. doi: 10.1016/s1043-6618(03)00158-0; Mullin S, Mani N, Grossman TH. Inhibition of antibiotic efflux in bacteria by the novel multidrug resistance inhibitors biricodar (VX-710) and timcodar (VX-853). *Antimicrob Agents Chemother* (2004) 48(11):4171-6. doi: 10.1128/AAC.48.11.4171-4176.2004; Ponte-Sucre A. Availability and applications of ATP-binding cassette (ABC) transporter blockers. *Appl Microbiol Biotechnol* (2007) 76(2):279-86. doi: 10.1007/s00253-007-1017-6; ABC Transporters and Cancer Drug Resistance (https://www.sigmaaldrich.com/VE/es/technical-documents/technical-article/research-and-disease-areas/cancer-research/abc-transporters-and-cancer-drug-resistance)

[b] First-generation inhibitors, **[c]** Second-generation inhibitors, **[d]** Third-generation inhibitors


frontiers